Difference between revisions of "Template:Estrogen dosages for prostate cancer"

From blackwiki
Jump to navigation Jump to search
imported>Trappist the monk
m (cite repair;)
(Add inline Template:Documentation; wrap references into it)
Line 51: Line 51:
 
|}<!--
 
|}<!--
  
--><noinclude>
+
--><noinclude>{{Documentation|content=
 
==See also==
 
==See also==
 
* [[Template:Estrogen dosages for menopausal hormone therapy]]
 
* [[Template:Estrogen dosages for menopausal hormone therapy]]
Line 58: Line 58:
 
==References==
 
==References==
 
{{Reflist}}
 
{{Reflist}}
 +
}}
 
[[Category:Medication templates]]
 
[[Category:Medication templates]]
 
[[Category:Templates that generate named references]]
 
[[Category:Templates that generate named references]]
 
</noinclude>
 
</noinclude>

Revision as of 16:44, 29 March 2019

Template:Ref info

Estrogen dosages for breast and prostate cancer

Route/form Estrogen Cancer Dosage Ref(s)
Oral Template:No selflink Breast 6–30 mg/day [1]
Template:No selflink Breast 10 mg 3x/day [2]
Prostate 1.25–2.5 mg 3x/day [2][3]
Template:No selflink Breast 1–3 mg/day [2][1]
Prostate 0.15–2 mg/day [2][3]
Template:No selflink Prostate 1–2 mg 1x/week [4][3]
Template:No selflink Breast 5 mg 3x/day [2]
Prostate 1–3 mg/day [2]
Template:No selflink Prostate 120–480 mg 1–3x/day [5][6]
Template:No selflink Prostate 12–25 mg/day [2]
Template:No selflink Prostate 140–1400 mg/day [7]
Transdermal patch Template:No selflink Prostate 2–6x 100 μg/day [8][9]
IM or SC injection Template:No selflink Prostate 1.66 mg 3x/week [10]
Template:No selflink Prostate 5 mg/1x week [10]
Template:No selflink Prostate 30 mg 1x/1–2 weeks [11]
Template:No selflink Prostate 100 mg/4 weeks [12]
Template:No selflink Breast 40–80 mg 1x/4 weeks [13]
Prostate 160–320 mg/1x 4 weeks [13][12]
Template:No selflink Prostate 2–4 mg 2–3x/week [2]
IV injection Template:No selflink Prostate 300–1200 mg 1–7x/week [5][6]
Template:No selflink Prostate 240–450 mg/day [7][14]
Note: Dosages are not necessarily equivalent.
Template documentation

See also

References

  1. 1.0 1.1 Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (January 2017). "The use of high-dose estrogens for the treatment of breast cancer". Maturitas. 95: 11–23. doi:10.1016/j.maturitas.2016.10.010. PMID 27889048.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1.
  3. 3.0 3.1 3.2 Oettel, M (1999). "Estrogens and Antiestrogens in the Male". In Michael Oettel; Ekkehard Schillinger (eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 505–571. doi:10.1007/978-3-642-60107-1_25. ISBN 978-3-642-60107-1. ISSN 0171-2004.
  4. Höfling, G.; Heynemann, H. (2014). "Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?" [Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?]. Der Urologe B. 38 (2): 165–170. doi:10.1007/s001310050185. ISSN 0042-1111.
  5. 5.0 5.1 Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2104–2105. ISBN 978-0-85369-840-1.
  6. 6.0 6.1 Franz von Bruchhausen; Gerd Dannhardt; Siegfried Ebel; August W. Frahm; Eberhard Hackenthal; Ulrike Holzgrabe (2 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O. Springer-Verlag. pp. 301–. ISBN 978-3-642-57994-3.
  7. 7.0 7.1 Perry CM, McTavish D (July 1995). "Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". Drugs Aging. 7 (1): 49–74. doi:10.2165/00002512-199507010-00006. PMID 7579781.
  8. Ockrim J, Lalani EN, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nat Clin Pract Oncol. 3 (10): 552–63. doi:10.1038/ncponc0602. PMID 17019433.
  9. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (May 2003). "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". J. Urol. 169 (5): 1735–7. doi:10.1097/01.ju.0000061024.75334.40. PMID 12686820.
  10. 10.0 10.1 "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy ed.). 10 (11): 692–694. 1949. doi:10.1016/S0095-9561(16)31995-8. ISSN 0095-9561.
  11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009402s052lbl.pdf
  12. 12.0 12.1 Norman G, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK, Sydes MR, Abel P, Eastwood AJ (February 2008). "Parenteral oestrogen in the treatment of prostate cancer: a systematic review". Br. J. Cancer. 98 (4): 697–707. doi:10.1038/sj.bjc.6604230. PMC 2259178. PMID 18268497.
  13. 13.0 13.1 http://pharmanovia.com/product/estradurin/
  14. Bergenheim AT, Henriksson R (February 1998). "Pharmacokinetics and pharmacodynamics of estramustine phosphate". Clin Pharmacokinet. 34 (2): 163–72. doi:10.2165/00003088-199834020-00004. PMID 9515186.